Human Biotransformation

Biotransformation and Metabolite Elucidation of Xenobiotics

Volumn , Issue , 2010, Pages 1-77

  Parkinson, Andrew ^a   Ogilvie, Brian W ^a   Paris, Brandy L ^a   Hensley, Tiffini N ^a   Loewen, Greg J ^a  

^a XenoTech LLC   (United States)

Author keywords

Drug biotransformation pathways their major subcellular locations; Human biotransformation; Perpetrator perpetrator victim interactions

Indexed keywords

EID: 84875472238     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470890387.ch1     Document Type: Chapter

References (107)

1. Akira K , Uchijima T , Hashimoto T . 2002 . Rapid internal acyl migration and protein binding of synthetic probenecid glucuronides . Chem Res Toxicol 15 : 765 - 772 .
2. Backman J , Kyrklund C , Neuvonen M , Neuvonen P . 2002 . Gemfi brozil greatly increases plasma concentrations of cerivastatin . Clin Pharmacol Ther 72 : 685 - 691 .
3. Barter ZE , Bayliss MK , Beaune PH , Boobis AR , Carlile DJ , Edwards RJ , Houston JB , Lake BG , Lipscomb JC , Pelkonen OR , Tucker GT , Rostami - Hodjegan A. 2007 . Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: Reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver . Curr Drug Metab 8 : 33 - 45 .
4. Bauman JN , Kelly JM , Tripathy S , Zhao SX , Lam WW , Kalgutkar AS , Obach RS . 2009 . Can in vitro metabolism - dependent covalent binding data distinguish hepatotoxic from nonhepatotoxic drugs? An analysis using human hepatocytes and liver S - 9 fraction . Chem Res Toxicol 22 ( 2 ): 332 - 340 .
5. Beconi MG , Mao A , Liu DQ , Kochansky C , Pereira T , Raab C , Pearson P , Lee Chiu S - H. 2003 . Metabolism and pharmacokinetics of a dipeptidyl peptidase IV inhibitor in rats, dogs, and monkeys with selective carbamoyl glucuronidation of the primary amine in dogs . Drug Metab Dispos 31 : 1269 - 1277 .
6. Beedham C. 2002 . Molybdenum hydroxylases . In Enzyme Systems That Metabolise Drugs and Other Xenobiotics , ed. Ioannides C , 147 - 187 . New York : Wiley .
7. Beedham C , Miceli JJ , Obach RS . 2003 . Ziprasidone metabolism, aldehyde oxidase, and clinical implications . J Clin Psychopharmacol 23 : 229 - 232 .
8. Benet LZ. 2009 . The drug transporter - metabolism alliance: Uncovering and defi ning the interplay . Mol Pharm 6 : 1631 - 1643 .
9. Benet LZ , Spahn - Langguth H , Iwakawa S , Volland C , Mizuma T , Mayer S , Mutschler E , Lin ET.. 1993 . Predictability of the covalent binding of acidic drugs in man . Life Sci 53 : PL141 - PL146 .
10. Bjornsson TD , Callaghan JT , Einolf HJ , Fischer V , Gan L , Grimm S , Kao J , King SP , Miwa G , Ni L , Kumar G , McLeod J , Obach RS , Roberts S , Roe A , Shah A , Snikeris F , Sullivan JT , Tweedie D , Vega JM , Walsh J , Wrighton SA. 2003a . The conduct of in vitro and in vivo drug - drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective . Drug Metab Dispos 31 : 815 - 832 .
11. Bjornsson TD , Callaghan JT , Einolf HJ , Fischer V , Gan L , Grimm S , Kao J , King SP , Miwa G , Ni L , Kumar G , McLeod J , Obach SR , Roberts S , Roe A , Shah A , Snikeris F , Sullivan JT , Tweedie D , Vega JM , Walsh J , Wirghton SA. 2003b . The conduct of in vitro and in vivo drug - drug interaction studies: A PhRMA perspective . J Clin Pharmacol 43 : 443 - 469 .
12. Boelsterli UA. 2002 . Xenobiotic acyl glucuronides and acyl CoA thioesters as protein -reactive metabolites with the potential to cause idiosyncratic drug reactions . Curr Drug Metab 3 : 439 - 445 .
13. Bolze S , Bromet N , Gay - Feutry C , Massiere F , Boulieu R , Hulot T. 2002 . Development of an in vitro screening model for the biosynthesis of acyl glucuronide metabolites and the assessment of their reactivity toward human serum albumin . Drug Metab Dispos 30 : 404 - 413 .
14. Boxenbaum H. 1980 . Interspecies variation in liver weight, hepatic blood fl ow, and antipyrine intrinsic clearance: Extrapolation of data to benzodiazapines and phenytoin . J Pharmacokinet Biopharm 8 : 165 - 176 .
15. Brunton LL , Lazo JS , Parker KL . 2006 . Goodman & Gilman ' s The Pharmacological Basic of Therapeutics , 11th ed . New York : McGraw - Hill .
16. Cashman J.. 1999 . In vitro metabolism: FMO and related oxygenations . In Handbook of Drug Metabolism , ed. Woolf EJ , 477 - 505. New York: Marcel Dekker .
17. Cashman JR , Zhang J . 2006 . Human fl avin - containing monooxygenases . Annu Rev Pharmacol Toxicol 46 : 65 - 100 .
18. Chu V , Einolf HJ , Evers R , Kumar G , Moore D , Ripp S , Silva J , Sinha V , Sinz M , Skerjanec A . 2009 . In vitro and in vivo induction of cytochrome p450: A survey of the current practices and recommendations: A Pharmaceutical Research and Manufacturers of America perspective . Drug Metab Dispos 37 : 1339 - 1354 .
19. Collins C , Levy R , Ragueneau - Majlessi I , Hachad H. 2006 . Prediction of maximum exposure in poor metabolizers following inhibition of nonpolymorphic pathways . Curr Drug Metab 7 : 295 - 299 .
20. Curran PG , DeGroot LJ.. 1991 . The effect of hepatic enzyme - inducing drugs on thyroid hormones and the thyroid gland . Endocr Rev 12 : 135 - 150 .
21. Ebner T , Heinzel G , Prox A , Beschke K , Wachsmuth H .. 1999 . Disposition and chemical stability of telmisartan 1 - O - acylglucuronide . Drug Metab Dispos 27 : 1143 - 1149 .
22. Evans DC , Watt AP , Nicoll - Griffith DA , Baillie TA. 2004 . Drug - protein adducts: An industry perspective on minimizing the potential for drug bioactivation in drug discovery and development . Chem Res Toxicol 17 : 3 - 16 .
23. Fisher M , Campanale K , Ackermann B , Vandenbranden M , Wrighton S. 2000a . In vitro glucuronidation using human liver microsomes and the pore - forming peptide alamethicin . Drug Metab Dispos 28 : 560 - 566 .
24. Fisher MB , VandenBranden M , Findlay K , Burchell B , Thummel KE , Hall SD , Wrighton SA. 2000b . Tissue distribution and interindividual variation in human UDP - glucuronosyltransferase activity: Relationship between UGT1A1 promoter genotype and variability in a liver bank . Pharmacogenetics 10 : 727 - 739 .
25. Fromm MF , Busse D , Kroemer HK , Eichelbaum M .. 1996 . Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin . Hepatology 24 : 796 - 801 .
26. Gasche Y , Daali Y , Fathi M , Chiappe A , Cottini S , Dayer P , Desmeules J . 2004 . Codeine intoxication associated with ultrarapid CYP2D6 metabolism . N Engl J Med 351 : 2827 - 2831 .
27. Giacomini KM , Sugiyama Y . 2006 . Membrane transporters and drug response . In Goodman & Gilman ' s The Pharmacological Basis of Therapeutics , ed. Goodman LS , Gilman A , Brunton LL , Lazo JS , Parker KL , 41 - 70 . New York : McGraw - Hill .
28. Giacomini KM , Huang SM , Tweedie DJ , Benet LZ , Brouwer KL , Chu X , Dahlin A , Evers R , Fischer V , Hillgren KM , Hoffmaster KA , Ishikawa T , Keppler D , Kim RB , Lee CA , Niemi M , Polli JW , Sugiyama Y , Swaan PW , Ware JA , Wright SH , Yee SW , Zamek - Gliszczynski MJ , Zhang L . 2010 . Membrane transporters in drug development . Nat Rev Drug Discov 9 : 215 - 236 .
29. Gertz M , Kilford PJ , Houston JB , Galetin A . 2008 . Drug lipophilicity and microsomal protein concentration as determinants in the prediction of the fraction unbound in microsomal incubations . Drug Metab Dispos 36 : 535 - 542 .
30. Gidal BE , Sheth R , Parnell J , Maloney K , Sale M . 2003 . Evaluation of VPA dose and concentration effects on lamotrigine pharmacokinetics: Implications for conversion to lamotrigine monotherapy . Epilepsy Res 57 : 85 - 93 .
31. Gipple KJ , Chan KT , Elvin AT , Lalka D , Axelson JE . 1982 . Species differences in the urinary excretion of the novel primary amine conjugate: Tocainide carbamoyl O - beta - D - glucuronide . J Pharm Sci 71 : 1011 - 1014 .
32. Goetz MP , Rae JM , Suman VJ , Safgren SL , Ames MM , Visscher DW , Reynolds C , Couch FJ , Lingle WL , Flockhart DA , Desta Z , Perez EA , Ingle JN . 2005 . Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of effi cacy and hot fl ashes . J Clin Oncol 23 : 9312 - 9318 .
33. Gonzalez FJ , Tukey RH . 2006 . Drug metabolism . In Goodman & Gilman ' s The Pharmacological Basis of Therapeutics , ed. Goodman LS , Gilman A , Brunton LL , Lazo JS , Parker KL , 71 - 91 . New York : McGraw - Hill .
34. Gorski J , Vannaprasaht S , Hamman M , Ambrosius W , Bruce M , Haehner - Daniels B , Hall S. 2003 . The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity . Clin Pharmacol Ther 74 : 275 - 287 .
35. Gorski JC , Huang SM , Pinto A , Hamman MA , Hilligoss JK , Zaheer NA , Desai M , Miller M , Hall SD . 2004 . The effect of echinacea ( Echinacea purpurea root) on cytochrome P450 activity in vivo . Clin Pharmacol Ther 75 : 89 - 100 .
36. Griffiths HH , Jones OO , Smith R . 2005 . Determination of microsomal and hepatocyte scaling factors for in vitro in vivo extrapolation . Drug Metab Rev 37 ( Suppl. 1 ): 71 .
37. Grimm SW , Einolf HJ , Hall SD , He K , Lim H - K , Ling K - HJ , Lu C , Nomeir AA , Seibert E , Skordos KW , Tonn GR , Van Horn R , Wang RW , Wong YN , Yang TJ , Obach RS. 2009 . The conduct of in vitro studies to address time - dependent inhibition of drug - metabolizing enzymes: A perspective of the Pharmaceutical Research and Manufacturers of America . Drug Metab Dispos 37 : 1355 - 1370 .
38. Guengerich FP.. 1991 . Reactions and signifi cance of cytochrome P - 450 enzymes . J Biol Chem 266 : 10019 - 10022 .
39. Guengerich FP. 2001 . Uncommon P450 - catalyzed reactions . Curr Drug Metab 2 : 93 - 115
40. Guengerich FP , MacDonald JS. 2007 . Applying mechanisms of chemical toxicity to predict drug safety . Chem Res Toxicol 20 : 344 - 369 .
41. Hakooz N , Ito K , Rawden H , Gill H , Lemmers L , Boobis AR , Edwards JE , Carlile DJ , Lake BG , Houston BJ . 2006 . Determination of a human hepatic microsomal scaling factor for predicting in vivo drug clearance . Pharm Res 23 : 533 - 539 .
42. Hansen - Moller J , Schmit U.. 1991 . Rapid high - performance liquid chromatography assay for the simultaneous determination of probenecid and its glucuronide in urine. Irreversible binding of probenecid to serum albumin . J Pharm Biomed Anal 9 : 65 - 73 .
43. Hallifax D , Houston JB . 2006 . Binding of drugs to hepatic microsomes: Comment and assessment of current prediction methodology with recommendation for improvement . Drug Metab Dispos 34 : 724 - 726 .
44. Hallifax D , Houston JB . 2007 . Saturable uptake of lipophilic amine drugs into isolated hepatocytes: Mechanisms and consequences for quantitative clearance prediction . Drug Metab Dispos 35 : 1325 - 1332 .
45. Hayakawa H , Fukushima Y , Kato H , Fukumoto H , Kadota T , Yamamoto H , Kuroiwa H , Nishigaki J , Tsuji A . 2003 . Metabolism and disposition of novel des - fl uoro quinolone garenoxacin in experimental animals and an interspecies scaling of pharmacokinetic parameters . Drug Metab Dispos 31 : 1409 - 1418 .
46. Holtbecker N , Fromm MF , Kroemer HK , Ohnhaus EE , Heidemann H .. 1996 . The nifedipine - rifampin interaction: Evidence for induction of gut wall metabolism . Drug Metab Dispos 24 : 1121 - 1123 .
47. Howgate EM , Rowland YK , Proctor NJ , Tucker GT , Rostami - Hodjegan A. 2006 . Prediction of in vivo drug clearance from in vitro data: I. Impact of inter - individual variability . Xenobiotica 36 : 473 - 497 . http://www.ema.europa.eu/ema/index.jsp?curl= pages/medicines/human/referrals/Cerivastatin/human_referral_000108.jsp&mid= WC0b01ac0580024e9a&murl=menus/regulations/regulations.jsp&jsenabled= true# (accessed July 22, 2010).
48. Huang SM , Strong JM , Zhang L , Reynolds KS , Nallani S , Temple R , Abraham S , Habet SA , Baweja RK , Burckart GJ , Chung S , Colangelo P , Frucht D , Green MD , Hepp P , Karnaukhova E , Ko HS , Lee JI , Marroum PJ , Norden JM , Qiu W , RahmanA , Sobel S , Stifano T , Thummel K , Wei XX , Yasuda S , Zheng JH , Zhao H , Lesko LJ . 2008 . New era in drug interactions evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process . J Clin Pharmacol 48 : 662 - 670 .
49. Johnson TN , Tucker G , Tanner MS , Rostami - Hodjegan A. 2005 . Changes in liver volume from birth to adulthood: A meta analysis . Liver Transplantation 12 : 1481 - 1493 .
50. Kanamitsu SI , Ito K , Sugiyama Y . 2000 . Quantitative prediction of in vivo drug - drug interactions from in vitro data based on physiological pharmacokinetics: Use of maximum unbound concentration of inhibitor at the inlet to the liver . Pharm Res 17 : 336 - 343 .
51. Kawashima K , Hosoi K , Naruke T , Shiba T , Kitamura M , Watabe T .. 1999 . Aldehyde oxidase - dependent marked species difference in hepatic metabolism of the sedative -hypnotic, zaleplon, between monkeys and rats . Drug Metab Dispos 27 : 422 - 428 .
52. Kiang TKL , Ensom MHH , Chang TKH . 2005 . UDP - glucuronosyltransferases and clinical drug - drug interactions . Pharmacol Ther 106 : 97 - 132 .
53. Koren G , Cairns J , Chitayat D , Gaedigk A , Leeder SJ . 2006 . Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine - prescribed mother . Lancet 368 : 704 .
54. Kumar S , Samual K , Subramanian R , Braun MP , Stearns RA , Chiu SL , Evans DC , Baillie TA . 2002 . Extrapolation of diclofenac clearance from in vitro microsomal metabolism data: Role of acyl glucuronidation and sequential oxidative metabolism of the acyl glucuronide . J Pharmacol Exp Ther 303 : 969 - 978 .
55. Lake BG , Ball SE , Kao J , Renwick AB , Price RJ , Scatina JA . 2002 . Metabolism of zaleplon by human liver: Evidence for involvement of aldehyde oxidase . Xenobiotica 32 : 835 - 847 .
56. Leone AM , Kao LM , McMillian MK , Nie AY , Parker JB , Kelley MF , Usuki E , Parkinson A , Lord PG , Johnson MD. 2007 . Evaluation of felbamate and other antiepileptic drug toxicity potential based on hepatic protein covalent binding and gene expression . Chem Res Toxicol 20 : 600 - 608 .
57. Li AP , Hartman NR , Lu C , Collins JM , Strong JM .. 1999 . Effects of cytochrome P450 inducers on 17alpha - ethinyloestradiol (EE2) conjugation by primary human hepatocytes . Br J Clin Pharmacol 48 : 733 - 742 .
58. Link M , Hakala KS , Wsol V , Kostiainen R , Ketola RA . 2006 . Metabolite profi le of sibutramine in human urine: A liquid chromatography - electrospray ionization mass spectrometric study . J Mass Spectrom 41 : 1171 - 1178 .
59. MacIntyre AC , Cutler DJ. 1988 . The potential role of lysosomes in tissue distribution of weak bases . Biopharm Drug Dispos 9 : 513 - 526 .
60. Madan A , Graham RA , Carroll KM , Mudra DR , Burton LA , Krueger LA , Downey AD , Czerwinski M , Forster J , Ribadeneira MD , Gan L - S , LeCluyse EL , Zech K , Robertson P Jr. , Koch P , Antonian L , Wagner G , Yu L , Parkinson A. 2003 . Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes . Drug Metab Dispos 31 : 421 - 431 .
61. Mahajan MK , Evans CA . 2008 . Dual negative precursor ion scan approach for rapid detection of glutathione conjugates using liquid chromatography/tandem mass spectrometry . Rapid Commun Mass Spectrom 22 : 1032 - 1040 .
62. Majerus PWT , Douglas M . 2006 . Blood conjugation and anticoagulant, thrombolytic, and antiplatelet drugs . In Goodman & Gilman ' s The Pharmacological Basis of Therapeutics , 11th ed. , ed. Goodman LS , Gilman A , Brunton LL , Lazo JS , Parker KL , 1200 - 1256 . New York : McGraw - Hill .
63. Mano Y , Usui T , Kamimura H . 2006 . In vitro drug interaction between difl unisal and indomethacin via glucuronidation in humans . Biopharm Drug Dispos 27 : 267 - 273 .
64. Masubuchi N , Makino C , Murayama N . 2007 . Prediction of in vivo potential for metabolic activation of drugs into chemically reactive intermediate: Correlation of in vitro and in vivo generation of reactive intermediates and in vitro glutathione conjugation formation in rats and humans . Chem Res Toxicol 20 : 455 - 464 .
65. Mikus G , Schowel V , Drzewinska M , Rengelshausen J , Ding R , Riedel KD , Burhenne J , Weiss J , Thomsen T , Haefeli WE . 2006 . Potent cytochrome P450 2C19 genotype -related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir . Clin Pharmacol Ther 80 : 126 - 135 .
66. Miners JO , Knights KM , Houston JB , Mackenzie PI . 2006 . In vitro - in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: Pitfalls and promises . Biochem Pharmacol 71 : 1531 - 1539 .
67. Naesens M , Kuypers DR , Streit F , Armstrong VW , Oellerich M , Verbeke K , Vanrenterghem Y . 2006 . Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: Implications for drug exposure in renal allograft recipients . Clin Pharmacol Ther 80 : 509 - 521 .
68. Nishiyama T , Kobori T , Arai K , Ogura K , Ohnuma T , Ishii K , Hayashi K , Hiratsuka A . 2006 . Identification of human UDP - glucuronosyltransferase isoform(s) responsible for the C - glucuronidation of phenylbutazone . Arch Biochem Biophys 454 : 72 - 79 .
69. Obach RS , Cox LM , Tremaine LM . 2005 . Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: An in vitro study . Drug Metab Dispos 33 : 262 - 270 .
70. Obach RS , Reed - Hagen AE , Krueger SS , Obach BJ , O ' Connell TN , Zandi KS , Miller S , Coe JW. 2006 . Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro . Drug Metab Dispos 34 : 121 - 130 .
71. Obach RS , Kalgutkar AS , Soglia JR , Zhao SX . 2008 . Can in vitro metabolism -dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose . Chem Res Toxicol 21 : 1814 - 1822 .
72. Ogilvie BW , Zhang D , Li W , Rodrigues AD , Gipson AE , Holsapple J , Toren P , Parkinson A . 2006 . Glucuronidation converts gemfi brozil to a potent, metabolism -dependent inhibitor of CYP2C8: Implications for drug - drug interactions . Drug Metab Dispos 34 : 191 - 197 .
73. Ogilvie BW , Usuki E , Yerino P , Parkinson A . 2008 . In vitro approaches for studying the inhibition of drug - metabolizing enzymes responsible for the metabolism of drugs (reaction phenotyping) with emphasis on cytochrome P450 . In Drug - Drug Interactions , 2nd ed. , ed. Rodrigues AD , 231 - 358 . New York : Informa Healthcare USA .
74. Otsuka M , Matsumoto T , Morimoto R , Arioka S , Omote H , Moriyama Y . 2005 . A human transporter protein that mediates the fi nal excretion step for toxic organic cations . PNAS 102 : 17923 - 17928 .
75. Ozdemir O , Boran M , Gokce V , Uzun Y , Kocak B , Korkmaz S . 2000 . A case with severe rhabdomyolysis and renal failure associated with cerivastatin - gemfi brozil combination therapy - A case report . Angiology 51 : 695 - 697 .
76. Paine MF , Widmer WW , Hart HL , Pusek SN , Beavers KL , Criss AB , Brown SS , Thomas BF , Watkins PB . 2006 . A furanocoumarin - free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice - felodipine interaction . Am J Clin Nutr 83 : 1097 - 1105 .
77. Parkinson A , Ogilvie BW . 2008 . Biotransformation of xenobiotics . In Casarett & Doull ' s Toxicology : The Basic Science of Poisons , 7th ed. , ed. Klaassen CD , 161 - 304 . New York : McGraw - Hill .
78. Pearce RE , Rodrigues AD , Goldstein JA , Parkinson A .. 1996 . Identification of the human P450 enzymes involved in lasoprazole metabolism . J Pharmacol Exp Ther 277 : 805 - 816 .
79. Pope LE , Khalil MH , Berg JE , Stiles M , Yakatan GJ , Sellers EM . 2004 . Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers . J Clin Pharmacol 44 : 1132 - 1142 .
80. Price PS , Conolly RB , Chaisson CF , Gross EA , Young JS , Mathis ET , Tedder DR . 2003 . Modeling interindividual variation in physiological factors used in PBPK models of humans . Crit Rev Toxicol 33 : 469 - 503 .
81. Proctor NJ , Tucker GT , Rostami - Hodjegan A. 2004 . Predicting drug clearance from recombinantly expressed CYPs: Intersystem extrapolation factors . Xenobiotica 34 : 151 - 178 .
82. Renwick AB , Ball SE , Tredger JM , Price RJ , Walters DG , Kao J , Scatina JA , Lake BG . 2002 . Inhibition of zaleplon metabolism by cimetidine in the human liver: In vitro studies with subcellular fractions and precision - cut liver slices . Xenobiotica 32 : 849 - 862 .
83. Rettie AE , Fisher MB .. 1999 . Transformation enzymes: Oxidative; non - P450 . In Handbook of Drug Metabolism , ed. Woolf T , 131 - 151 . New York : Marcel Dekker, Inc .
84. Schrag ML , Cui D , Rushmore TH , Shou M , Ma B , Rodrigues AD . 2004 . Sulfotransferase 1E1 is a low km isoform mediating the 3 - O - sulfation of ethinyl estradiol . Drug Metab Dispos 32 : 1299 - 1303 .
85. Shiraga T , Niwa T , Ohno Y , Kagayama A . 2004 . Interindividual variability in 2 - hydroxylation, 3 - sulfation, and 3 - glucuronidation of ethynylestradiol in human liver . Biol Pharm Bull 27 : 1900 - 1906 .
86. Shitara Y , Hirano M , Sato H , Sugiyama Y . 2004 . Gemfi brozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6) -mediated hepatic uptake and CYP2C8 - mediated metabolism of cerivastatin: Analysis of the mechanism of the clinically relevant drug - drug interaction between cerivastatin and gemfi brozil . J Pharmacol Exp Ther 311 : 228 - 236 .
87. Shitara Y , Horie T , Sugiyama Y . 2006 . Transporters as a determinant of drug clearance and tissue distribution . Eur J Pharm Sci 27 : 425 - 446 .
88. Shu Y , Sheardown SA , Brown C , Owen RP , Zhang S , Castro RA , Ianculescu AG , Yue L , Lo JC , Burchard EG , Brett CM , Giacomini KM . 2007 . Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action . J Clin Invest 117 : 1422 - 1431 .
89. Soars MG , Burchell B , Riley RJ . 2002 . In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance . J Pharmacol Exp Ther 301 : 382 - 390 .
90. Strelevitz TJ , Foti RS , Fisher MB . 2006 . In vivo use of the P450 inactivator 1 - aminobenzotriazole in the rat: Varied dosing route to elucidate gut and liver contributions to fi rst - pass and systemic clearance . J Pharm Sci 95 : 1334 - 1341 .
91. Sugihara K , Kitamura S , Tatsumi K .. 1996 . Involvement of mammalian liver cytosols and aldehyde oxidase in reductive metabolism of zonisamide . Drug Metab Dispos 24 :. 199 - 202 .
92. Takakusa H , Masumoto H , Yukinaga H , Makino C , Nakayama S , Okazaki O , Sudo K. 2008a . Covalent binding and tissue distribution/retention assessment of drugs associated with idiosyncratic drug toxicity . Drug Metab Dispos 36 : 1770 - 1779 .
93. Tirmenstein MA , Nelson SD . 1989 . Subcellular binding and effects on calcium homeostasis produced by acetaminophen and a nonhepatotoxic regioisomer, 3 '?- hydroxyacetanilide, in mouse liver . J Biol Chem 264 : 9814 - 9819 .
94. Treiber A , Schneiter R , Delahaye S , Clozel M . 2004 . Inhibition of organic anion transporting polypeptide - mediated hepatic uptake is the major determinant in the pharmacokinetic interaction between bosentan and cyclosporin A in the rat . J Pharmacol Exp Ther 308 : 1121 - 1129 .
95. Tremaine LM , Stroh JG , Ronfeld RA . 1989 . Characterization of a carbamic acid ester glucuronide of the secondary amine sertraline . Drug Metab Dispos 17 : 58 - 63 .
96. Tsunoda SM , Velez RL , von Moltke LL , Greenblatt DJ.. 1999 . Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as in vivo probe: Effect of ketoconazole . Clin Pharmacol Ther 66 : 461 - 471 .
97. Tucker GT , Houston JB , Huang SM . 2001 . Optimizing drug development: Strategies to assess drug metabolism/transporter interaction potential - Toward a consensus .Pharm Res 18 : 1071 - 1080 .
98. US Food and Drug Administration (US FDA) . 2006 . Draft Guidance for Industry: Drug Interaction Studies - Study Design , Data Analysis and Implications for Dosing and Labeling. http://www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/UCM072101.pdf .
99. US Food and Drug Administration (US FDA) . 2008 . Guidance for Industry Safety Testing of Drug Metabolites . http://www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/Guidances/ucm079266.pdf.
100. Williams RT. 1959 . Detoxication Mechanisms: The Metabolism and Detoxication of Drugs, Toxic Substances, and Other Organic Compounds , 2nd ed . New York : Wiley .
101. Williams JA , Hurst SI , Bauman J , Jones BC , Hyland R , Gibbs JP , Obach RS , Ball SE . 2003 . Reaction phenotyping in drug discovery: Moving forward with confi dence? Curr Drug Metab 4 : 527 - 534 .
102. Williams JA , Hyland R , Jones BC , Smith DA , Hurst S , Goosen TC , Peterkin V , Koup JR , Ball SE . 2004 . Drug - drug interactions for UDP - glucuronosyltransferase substrates: A pharmacokinetic explanation for typically observed low exposure (AUCI/ AUC) ratios . Drug Metab Dispos 32 : 1201 - 1208 .
103. Wu CY , Benet LZ . 2005 . Predicting drug disposition via application of BCS: Transport/ absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system . Pharm Res 22 ( 1 ): 11 - 23 .
104. Youdim KA , Zayed A , Dickins M , Phipps A , Griffiths M , Darekar A , Hyland R , Fahmi O , Hurst S , Plowchalk DR , Cook J , Guo F , Obach RS . 2008. Application of CYP3A4 in vitro data to predict clinical durg - durg interactions; predictions of compounds as objects of interaction . Br J Clin Pharmacol 65 : 680 - 692 .
105. Zhang J , Visser F , Vickers MF , Lang T , Robins MJ , Nielsen LPC , Nowak I , Baldwin SA , Young JD , Cass CE . 2003 . Uridine binding motifs of human concentrative nucleoside transporters 1 and 3 produced in Saccharomyces cerevisiae . Mol Pharmacol 64 : 1512 - 1520 .
106. Zhang L , Zhang YD , Zhao P , Huang SM . 2009 . Predicting drug - drug interactions: An FDA perspective . AAPS J 11 : 300 - 306 .
107. Zineh I , Beitelshees AL , Gaedigk A , Walker JR , Pauly DF , Eberst K , Leeder JS , Phillips MS , Gelfand CA , Johnson JA . 2004 . Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or effi cacy in hypertension . Clin Pharmacol Ther 76 : 536 - 544 .